XW Laboratories: XW Labs Starts Phase I Trial of Novel Narcolepsy Candidate

XW Labs a CNS company with R&D operations in Wuhan and Taipei will start an Australian Phase I trial of its lead candidate. XW10172 is a small molecule treatment aimed at narcolepsy. The trial will enroll patients who have type 1 narcolepsy with ex...